Krystal Biotech KRYS Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, Krystal Biotech insiders sold $95.24 million of stock on the open market (335.66K shares) and made no open-market purchases.

• By number of insiders, Krystal Biotech saw 6 insiders sell on the open market over the past 12 months and none buy.
• The largest open-market sales of KRYS in the past 12 months were by Krish S. Krishnan (President and CEO), totaling $34.27 million (125K shares), most recently on September 4, 2026.
• Apart from open-market trades, KRYS insiders acquired 212.84K shares through option exercises and conversions, gave up 64.67K shares to cover taxes or exercise prices and gave away 14.44K shares as gifts in the past 12 months.
• According to Business Quant data, insiders at Krystal Biotech reported 5.72Mn shares in total in their latest Form 4 filings, or 19.34% of the 29.6Mn shares outstanding; that total is down 7.64% from 6.2Mn shares at the end of Q2 2026.
• Direct holdings account for 2.72Mn shares (47.56%) of KRYS's insider total, and indirect holdings through trusts, partnerships and family members for 3Mn shares (52.44%).
• The insider holdings in Krystal Biotech belong to 5 insiders who have reported on Form 4 within the past two years.
• Krystal Biotech's top three insider holders by shares held are Suma Krishnan (President, R&D, 2.8Mn shares), Krish S. Krishnan (President and CEO, 2.78Mn shares) and Daniel Janney (Director, 73.29K shares).
• Suma Krishnan alone accounts for 48.96% of the shares held by Krystal Biotech insiders.
• In the past year, 10 insiders of Krystal Biotech submitted 24 Form 4 filings reporting trades, awards or other transactions.
• The insider data for KRYS reflects Form 4 filings through September 16, 2026.